Neuland Laboratories posts blockbuster FY26 performance

Neuland Laboratories elevates Saradhi Bolli to Global Head of CDMO Business Development

Bolli will lead worldwide business development for the company’s Contract Development and Manufacturing Organisation (CDMO) services

Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26

The revenues this quarter are in line with the outlook we envisaged for the year

Briefs: Neuland Laboratories and Granules India

Granules India receives 1 observation from USFDA for Chantilly facility

Neuland Laboratories posts Q4 FY25 consolidated PAT at Rs. 27.80 Cr

The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025

Neuland Laboratories completes USFDA inspection at Unit 2

The FDA issued Form 483 with one observation related to building and facility management

Neuland Laboratories Q2 FY25 consolidated PAT falls to Rs. 32.84 Cr

Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024

Neuland Laboratories posts Q4 FY24 consolidated PAT at Rs. 67.56 Cr

Neuland Laboratories has reported total income of Rs. 390.36 crores during the period ended March 31, 2024

Briefs: Concord Biotech and Neuland Laboratories

The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483

Briefs: Neuland Laboratories, Cipla and Zydus

Cipla has received 8 inspectional observations in Form 483